Table 4 Probability that palivizumab is cost-effective for different WTP thresholds
Sub-group | WTP threshold £20,000 | WTP threshold £30,000 |
|---|---|---|
CHD | 36.76% | 51.52% |
CLD | 45.04% | 60.06% |
<29 wGA | 45.02% | 51.22% |
29-32 wGA | 30.44% | 36.78% |
33-35 wGA | 2.8% | 5.4% |
Sub-group | WTP threshold £20,000 | WTP threshold £30,000 |
|---|---|---|
CHD | 36.76% | 51.52% |
CLD | 45.04% | 60.06% |
<29 wGA | 45.02% | 51.22% |
29-32 wGA | 30.44% | 36.78% |
33-35 wGA | 2.8% | 5.4% |